Bristol-myers Squibb Stock News

Berkshire Bought Activision In Q4 Ahead Of Microsoft Purchase; Added To Chevron, Trimmed Visa, Mastercard And Pharma Stocks In the weeks before Microsoft made the surprise announcement it was acquiring the troubled Activision, the market was rife with speculation that Berkshire itself could make a play - no pun intended - for the foundering video game company whose stock had tumbled so much in the fourth quarter amid poor earnings and sexual harassment scandals, many viewed it as a deep value play suitable even for Warren Buffett. In retrospect, that didn''t pan out, but as we learned today after the quarterly 13F bonanza hit, Berkshire was buying Activision in Q4 when the stock was tumbling, and as of Dec 31, Berkshire owned 14.658 million shares of Activision stock, representing 1.9% of the shares outstanding. Assuming Buffett bought around the average price for the quarter, or $65, Berkshire made around $250 million on that purchase alone which is not a bad payout for a few weeks worth of work (one wonders if the information that Buffett was buying somehow leaked, and prompted Microsoft''s unexpected acquisition of ATVI).

The conglomerate also adds to its Chevron holding, while cutting back on Bristol Myers Squibb and AbbVie.

Warren Buffett''s Berkshire Hathaway Inc said on Monday it added nearly 14.7 million shares of video game maker Activision Blizzard Inc ahead of Microsoft Corp''s $68.7 billion deal to buy the company. The company also added to its position in energy giant Chevron Corp while slicing its position in healthcare names including Bristol-Myers Squibb Co and Abbvie Inc during the quarter that ended in December. The changes were disclosed in a regulatory filing detailing Berkshire''s U.S.-listed holdings at the end of the year.

Warren Buffett once again was a net seller of equities in the fourth quarter, slicing, slashing and outright exiting stakes across a series of sectors that have fallen out of his favor. But the Oracle

Burry's Scion Asset Management swapped out four of its six US stocks last quarter, helping to boost its portfolio's value by 78%.

These Berkshire Hathaway stocks are trading at reasonable valuations for their quality.

Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals are highlighted in this Industry Outlook article.

Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.

Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.

There are several ways that a company can return wealth to its shareholders. Price appreciation and dividends are the two most common ways, but there are other ways a company can introduce returns to

3 Companies With Safe Yield And Significant Upside

The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.

Earnings updates from Bristol-Myers (BMY), Amgen (AMGN) and others are among the few key highlights from the biotech sector during the past week.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Humanigen Announces Agreement With French CDMO For Fill And Finish Services For Lenzilumab Humanigen,